http://www.psychcongress.com/article/alkermes-submits-dual-indication-nda-alks-3831
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
The once-daily oral atypical antipsychotic is designed to provide the efficacy of olanzapine while mitigating weight gain often associated with it.
olanzapine worked so good for my symptoms but made me want to eat all the time and couldnt control it, gained alot of weight, also i kind of messed myself up somehow when taking it along with other stuff and it stopped working as well as it used to.
i wonder why an opioid antagonist combats some of the weight gain (doesnt seem like enough from the study i saw as even a 37% decrease in weight gain would still mean gaining a lot of weight still.
seemed like olanzapine + lorcaserin (5ht2c agonist) was much better for the weight part but lorcaserin still doesnt have a generic as its still new.
They need to do this across the board, not just with olanzapine.
Triphecta, it’s a combination AP AD and MS.
Would sell amazingly